Health Care/Hospital News & Press Release Distribution

Health Care/Hospital

APAC
Global

Onward Therapeutics Announces Enrollment of Phase 1 Clinical Trial of a Novel Bispecific Antibody (OT-A201) Targeting Two Immune Checkpoints

EPALINGES, Switzerland and PARIS, Jan. 24, 2024 /PRNewswire/ -- Onward Therapeutics SA (Onward Therapeutics), a global biotechnology company focused on developing innovative immunotherapies for cancer treatment, today announced that the phase 1 clinical trial of OT-A201 (Study No. A20101), a firs...

2024-01-24 15:00 1219

Harbour BioMed Announces IND Clearance for HBM9027 in the U.S.

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SUZHOU, China, Jan. 23, 2024 /PRNewswire/ -- Harbour BioMed (the "Company", HKEX: 02142) announced that the Company has been granted the clearance of Investigational New Drug (IND) from the Food and Drug Administration (FDA) ofthe United States to init...

2024-01-24 12:40 1229

WuXi XDC and Celltrion Sign MOU for Integrated Services for Antibody-Drug Conjugates (ADCs)

SHANGHAI and INCHEON, South Korea, Jan. 23, 2024 /PRNewswire/ -- WuXi XDC(2268.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO) focused on ADC and the other types of bioconjugate market, and Celltrion, Inc. (068270.KS), a leading global biopharmaceutical...

2024-01-24 11:37 1144

PharmAbcine Announces First Patient Dosed in Phase 1a/b Clinical Trial of PMC-309 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Advanced or Metastatic Solid Tumors

* Initiation of Phase 1a/b clinical trial exploring MTD, RP2D, safety and tolerability of PMC-309 monotherapy and combination therapy with KEYTRUDA® * The clinical trial aims to enroll a total of 67 patients across four institutions inAustralia DAEJEON, South Korea, Jan. 23, 2024 /PRNewswire/ ...

2024-01-24 10:01 1039

Sciwind Biosciences Announces Positive Results from Phase 1 Clinical Trial of XW004, an Oral Formulation of Long-acting GLP-1 Analog Ecnoglutide

* Oral ecnoglutide was safe and well tolerated with gastrointestinal side effects as the most commonly reported adverse events * Study participants receiving up to 30 mg oral ecnoglutide once-daily for 6 weeks achieved a mean body weight reduction of -6.8% from baseline, compared to -0.9% for...

2024-01-24 10:00 1250

INTREPID Alliance Releases Review of Antiviral Compounds in Clinical Development to Contribute to Collaborative Efforts in Pandemic Preparedness

Global landscape analysis identifies strengths and gaps in R&D pipeline to inform international pandemic preparedness efforts ROME and CAMBRIDGE, Mass., Jan. 24, 2024 /PRNewswire/ -- The INTREPID Alliance, a consortium of innovative biopharmaceutical companies dedicated to accelerating the devel...

2024-01-24 08:22 1243

Datasea Pre-Announces First Half 2024 Revenue of $18.2 Million, a 1,037.5% Year-Over-Year Increase

BEIJING, Jan. 23, 2024 /PRNewswire/ -- Datasea Inc., (NASDAQ: DTSS) ("Datasea" or the "Company"), aNevada incorporated digital technology corporation engaged in converging and innovative business segments for intelligent acoustics and 5G messaging technology inChina pre-announced that its revenue...

2024-01-23 22:35 2987

Rhino Rescue Speeds into the Future of First-Aid Supplies with New Year Resolutions for 2024

Propelling Lifesaving Measures with User-friendly Innovations in 2024 SHANGHAI, Jan. 23, 2024 /PRNewswire/ -- As the New Year unfolds, Rhino Rescue , a global innovator in premier first-aid supplies, would like to take a moment to reflect upon and celebrate its rem...

2024-01-23 22:15 1433

Rhino Rescue Speeds into the Future of First-Aid Supplies with New Year Resolutions for 2024

IMG Mobile App Now Available with 24/7 Access to Coverage for All Customers

INDIANAPOLIS, Jan. 23, 2024 /PRNewswire/ -- IMG (International Medical Group), an award-winning global insurance benefits and assistance services company, is happy to announce its award-winning mobile app, IMG Mobile, is now available to all IMG customers. While previously available to select cu...

2024-01-23 22:00 1476

Stena Sessan AB requests compulsory buy-out and Concordia Maritime applies for delisting

GOTHENBURG, Sweden, Jan. 23, 2024 /PRNewswire/ -- Stena Sessan AB ('Stena Sessan'), which holds more than 90 per cent of the shares and votes in Concordia Maritime AB (publ) ('Concordia Maritime'), has requested that a compulsory buy-out of the remaining shares in Concordia Maritime be initiated....

2024-01-23 21:32 1382

Caliway Received First Approval of CBL-514 Pivotal Phase 3 Study Application for Subcutaneous Fat Reduction

NEW TAIPEI CITY, Jan. 23, 2024 /PRNewswire/ -- Caliway Biopharmaceuticals (Caliway) announces that Australian Bellberry HREC has approved Caliway's application to initiate CBL-514's Pivotal Phase 3 study (CBL-0301) for subcutaneous fat reduction. "We are all delighted to see CBL-514 showing its ...

2024-01-23 21:12 1345

Metabolon and Sheffield Institute for Translational Neuroscience Join Forces to Propel ALS Research and Biomarker Discovery

Collaboration aims to transform research to improve patient outcomes and enhance the understanding of ALS and motor neuron diseases (MND) MORRISVILLE, N.C., Jan. 23, 2024 /PRNewswire/ -- Metabolon, Inc., the global leader in providing metabolomics solutions advancing a wide variety of life scien...

2024-01-23 21:03 1332

Akeso Presented Promising Results of Cadonilimab and Lenvatinib in Combination with TACE in uHCC at 2024 ASCO GI

HONG KONG, Jan. 23, 2024 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso," "we," or the "Company") today announced that the Company presented the promising phase II results of cadonilimab (a tetravalent PD-1/CTLA-4 bispecific antibody) and Lenvatinib (Len) combined with TACE for the treatment of mi...

2024-01-23 21:00 2834

Caliway Received First Approval of CBL-514 Pivotal Phase 3 Study Application for Subcutaneous Fat Reduction

NEW TAIPEI CITY, Jan. 23, 2024 /PRNewswire/ -- Caliway Biopharmaceuticals (Caliway) announces that Australian Bellberry HREC has approved Caliway's application to initiate CBL-514's Pivotal Phase 3 study (CBL-0301 Phase 3) for subcutaneous fat reduction. "We are all delighted to see CBL-514 show...

2024-01-23 18:35 1000

Baird Medical Performs First Thyroid Microwave Ablation Procedure in the United States

FRISCO, Texas, Jan. 23, 2024 /PRNewswire/ -- Baird Medical Devices, Inc. ("Baird Medical" or the "Company"), a leading microwave ablation ("MWA") medical device developer and provider inChina and the United States, today announced that it has performed its first thyroid MWA procedure inthe United...

2024-01-23 18:00 1093

FDA Grants Breakthrough Device Designation to Amadix´s preventive screening blood test for Colorectal Cancer

* PreveCol®, a blood test for oncological diagnosis, has obtained US recognition for its efficacy in detecting precancerous lesions compared to existing alternatives inthe United States. * Amadix becomes the first European company to announce this recognition for early detection of colorectal...

2024-01-23 18:00 1693

Apollo Cancer Centres launches India's 1st AI-Precision Oncology Centre

BENGALURU, India, Jan. 23, 2024 /PRNewswire/ -- In a significant move that will substantially enhance the quality of oncology care,Apollo Cancer Centre , Bengaluru, launched India's first AI-Precision Oncology Centre (POC). The Centre will...

2024-01-23 16:27 1253

Apollo Cancer Centres launches India's 1st AI-Precision Oncology Centre

2024 Japan Prize Laureates Announced

TOKYO, Jan. 23, 2024 /PRNewswire/ -- The Japan Prize Foundation announced the winners of the 2024 Japan prize onJanuary 23, 2024. Prof. Sir Brian J. Hoskins (UK) and Prof.John Michael Wallace (USA) are co-winners of the Japan Prize in the fields of Resources, Energy, the Environment, and Social I...

2024-01-23 14:00 605

Gannex's Strategic Partner Sagimet Biosciences Announces Positive Topline Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 NASH

Denifanstat achieved statistically significant results on primary and multiple secondary endpoints in a 52-week clinical trial of 168 NASH patients with stage 2 or 3 fibrosis - Primary efficacy endpoints: * NASH resolution without worsening of fibrosis with ≥2-point reduction in NAS (NAFLD A...

2024-01-23 12:17 1341

European Medicines Agency (EMA) Grants Orphan Drug Designation (ODD) to GC Biopharma's Treatment for Sanfilippo Syndrome (Type A)

YONGIN, South Korea, Jan. 22, 2024 /PRNewswire/ -- GC Biopharma Corp. (006280.KS) announced that the European Medicines Agency (EMA) has granted Orphan Drug Designation (ODD) to its intracerebroventricular (ICV) Enzyme Replacement Therapy (ERT) candidate, GC1130A, designed for Sanfilippo Syndrome...

2024-01-23 11:53 1222

1 ... 40 41 424344 45 46 ... 808